ETFs with Biogen Inc BIIB Exposure

Exchanges report short interest twice a month.Percent of FloatTotal short positions relative to the number of shares available to trade. Biogen Inc. stock rose 3% in premarket trade Wednesday, after a new study was unveiled late Tuesday that showed the company’s experimental Alzheimer’s drug being developed with Japan’s Eisai The study assessing lecanemab… On top of that, its forward price-to-earnings ratio of 12.71 is slightly higher than the biotech industry’s average of 11.2. The company has been highly successful over the years, and with its long-standing leadership in the pharmaceutical industry, it could stage a strong comeback eventually. Amylyx has won approval for a drug to treat the condition known as Lou Gehrig’s disease. (herraez —, the oncology field benefited from regulatory flexibility in a way the neuroscience field can’t — at least not yet.

Biogen Inc stock

This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market. Robinhood gives you the tools you need to put your money in motion. The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled BIIB stock price the S&P 500 with an average gain of +24.51% per year. These returns cover a period from January 1, 1988 through September 12, 2022. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return.

Oil Jumps On OPEC Output Agreement, Russia Price Cap, China Demand Bets

Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Biogen Inc. shares have plunged by nearly 23 percent since January 26, falling to $283 per share. But signs are emerging that a reversal might be in order over the short term based on an analysis of the stock’s trading pattern. Forex The current setup in the chart suggests the biotech company may climb by as much as 14 percent. But the longer-term growth prospects for Biogen are muted, with analysts only expecting growth of 5.7 percent. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of seve…

Biogen Inc stock

For Biogen stock, lecanemab represents a second chance at an Alzheimer’s approval. Biogen also won an accelerated approval for a similar drug, Aduhelm. Both Aduhelm and lecanemab remove built-up plaque in the brain known as amyloid.

Pharma Stock Roundup: PFE & AZN Ink New M&A Deals, LLY Meets Alzheimer’s Study Goal

Also known as Lou Gehrig’s disease, the muscular condition is progressive and nearly always fatal. Meanwhile, Biogen recently shocked Wall Street with promising results in Alzheimer’s disease. Like Amylyx’s approval, Biogen’s single Phase 3 study could be enough to prompt a rapid approval and boost Biogen stock.

  • But this high-profile regulatory success hasn’t been enough to help Biogen’s stock, and some serious questions remain about the new medication.
  • Executives and analysts expect companies to swarm the neuroscience realm in an effort to tackle conditions previously believed to be untreatable.
  • Biogen Inc. shares have plunged by nearly 23 percent since January 26, falling to $283 per share.
  • A bear trap denotes a decline that fools market participants into opening short positions ahead of an upside reversal that squeezes those positions into losses.

“Wall Street generally likes to look for new thematic areas of growth both based on clinical data and the regulatory environment, and I think we’re starting to see this here,” he said. “It’s nowhere near consensus yet, but it very well could be the start of garnering more investment dollars, be it from investors or strategics.” “We have been seeing a neuro dotbig explosion in terms of scientific data and access to data,” she said. Biogen has a long history of examining the genetics of neurodegenerative diseases, says Priya Singhal, the company’s head of global safety and regulatory sciences, and interim head of research and development. Now, the broader industry is moving in that direction, she told IBD.

Related Companies

The company is still dealing with the fallout of a controversial regulatory approval. IBD Videos Get market updates, educational videos, webinars, and stock analysis. “There were innovative advancements, but not necessarily all applicable to the overall population,” Wedbush’s Chico said. “I think as we’re trying to design new therapies, it goes hand in hand to be able to identify the population that’s most applicable or relevant to your program.” Another example is Biogen’s and Ionis Pharmaceuticals’ tofersen, a potential treatment for a rare form of ALS tied to a mutation in a gene called SOD1.

Is Biogen Stock a Buy Now?

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. One share of BIIB stock can currently be purchased for approximately $298.90. The company is scheduled to release its next quarterly earnings BIIB stock price announcement on Thursday, February 2nd 2023. High institutional ownership can be a signal of strong market trust in this company. In the past three months, Biogen insiders have sold more of their company’s stock than they have bought.

Stock Money Flow

The value of investments can go up as well as down and you may receive back less than your original investment. As all investments carry risk, before making any investment decision, consider if it’s right for you and seek appropriate advice from a licensed tax or financial advisor. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided. The Zacks Rank system, which ranges from #1 to #5 , has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988.

This change was narrower than the S&P 500’s daily loss of 0.65%. Elsewhere, the Dow gained 0.12%, while the tech-heavy Nasdaq added 0.03%. The Relative Strength Index is a momentum indicator that measures the magnitude of recent price changes to analyze overbought or oversold conditions. Moving average convergence/divergence is a momentum indicator that shows the relationship between two moving averages of a security’s price. For now, the technicals are pointing to a stock that can rise over the short-term, but the longer-term picture for Biogen remains a little murky. To see a complete breakdown of any of the ETFs included in the table below, including sector, market cap, and country allocations, click on the ticker symbol. Holdings data are updated once a day, and are subject to change.

Tags: No tags

Add a Comment

Your email address will not be published. Required fields are marked *